NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to ALVO. ALVO was compared to 556 industry peers in the Biotechnology industry. ALVO has a medium profitability rating, but doesn't score so well on its financial health evaluation. ALVO is not overvalued while it is showing excellent growth. This is an interesting combination.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.75% | ||
ROE | N/A | ||
ROIC | 10.37% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 21.88% | ||
PM (TTM) | 16.42% | ||
GM | 60.74% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | 0.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.73 | ||
Quick Ratio | 1.19 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 17.47 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 39.95 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
8.64
+0.01 (+0.12%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 17.47 | ||
P/S | 8.92 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | 39.95 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.75% | ||
ROE | N/A | ||
ROCE | 13.13% | ||
ROIC | 10.37% | ||
ROICexc | 10.8% | ||
ROICexgc | 11.19% | ||
OM | 21.88% | ||
PM (TTM) | 16.42% | ||
GM | 60.74% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 7.35 | ||
Cap/Depr | 234.04% | ||
Cap/Sales | 12.89% | ||
Interest Coverage | 2.32 | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.73 | ||
Quick Ratio | 1.19 | ||
Altman-Z | 0.43 |